SecBot SecBot
424B5 ·Filed Nov 12, 2026

VIR

Vir Biotechnology, Inc.
BEARISH
Impact 5/10
Horizondays Processed4d 7h ago SEC0001193125-26-458462
Notable filing: 424B5
Actionable Insight ▼ Bearish

Monitor the final pricing and share count when the supplement is completed. The offering size relative to market cap will determine the degree of dilution. The company's cash runway extends into H2 2028, so this raise appears opportunistic following positive trial data rather than distress-driven.

DirectionBearish
Confidencemedium
Horizondays

Drugs in focus

VIR drug pipeline →

elebsiran

▲ Bullish Named in this 424B5
Impact
Phase
Phase 3
Time to market
If Phase 3 ECLIPSE 1 results are positive, regulatory filings could follow in 2027, with potential FDA approval in 2027-2028 given the Breakthrough Therapy designation enabling expedited review.
Next catalyst
None dated

What to watchThe pivotal Phase 3 ECLIPSE 1 topline results for elebsiran plus tobevibart in chronic hepatitis delta will be presented as a late-breaking oral at AASLD on November 8, 2026, with an investor call on November 9. Positive data would support regulatory filings and validate the combination against bulevirtide; negative or mixed results would severely damage the company's lead program thesis. The stock surged ~11% on November 6 ahead of the readout, reflecting anticipation.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$9.96
T+0 close · Nov 12, 2026 · via day close
Latest settled
−3.82%
T+1 · $9.58
Vs SPY
−1.90%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $9.96entry
  2. T+1 · 17h ago −3.82%α −1.90% · $9.58
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vir Biotechnology filed a preliminary prospectus supplement for an underwritten public offering of common stock, with size, price, and other terms left as placeholders. The offering follows positive Phase 3 ECLIPSE 1 data for its CHD program and a recent Gilead collaboration. Proceeds will fund pre-commercial activities for the CHD program, TCE oncology platform investments, and general corporate purposes.

Key Financial Metrics

Lock-up
60 days
Underwriters
Leerink Partners LLC, Morgan Stanley & Co. LLC +2

Key Facts

  • Preliminary prospectus supplement for an underwritten common stock offering filed on November 12, 2026.
  • Share count, public offering price, underwriting discounts, and net proceeds are all placeholders (TBD).
  • Last reported sale price on November 11, 2026 was $13.13 per share.
  • Underwriters have a 30-day option to purchase additional shares.
  • Proceeds will fund pre-commercial CHD activities, TCE oncology platform investments, and general corporate purposes.
  • Company had $901.3M in cash and investments as of September 30, 2026, plus $90M from a Gilead collaboration in October 2026.
  • Positive Phase 3 ECLIPSE 1 topline data announced in November 2026; ECLIPSE 2 and 3 data expected Q1 2027.
  • Net tangible book value per share as of September 30, 2026 was $5.14.
  • Lock-up period of 60 days for company, executive officers, and directors.

Financial Impact

Offering size not yet disclosed; based on 169.4M shares outstanding and $13.13 price, a 10% offering (~17M shares) would raise ~$223M. Dilution could be material depending on final size.

dilutioncash

Risk Factors

  • Offering size and price are not yet finalized; dilution cannot be quantified until pricing.
  • Equity issuance dilutes existing shareholders; the company has $901.3M cash and may not need the capital near-term.
  • Clinical-stage biotech with no approved products; regulatory and commercial risks remain high.

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-458462
Document: 0001193125-26-458462-index-headers.html0001193125-26-458462
Document: 0001193125-26-458462-index.html0001193125-26-458462
Document: 0001193125-26-458462.txt0001193125-26-458462

Track record

36 reports on VIR

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 4 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Viewing Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026